Processa Pharmaceuticals, Inc., formerly Heatwurx, Inc., is a pharmaceutical company. The Company is focused on the development of drug products that are intended to improve the survival and/or quality of life for patients who have unmet medical need. The Company’s product portfolio includes 499. It is developing 499 for the treatment of Necrobiosis Lipoidica. It is also developing 499 for the treatment of effects related to head and neck cancer.